Humacyte's ATEV increases catheter-free days in women in Phase 3 dialysis trial

Bitget2026/10/23 12:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Humacyte’s Phase 3 V012 interim results showed its bioengineered vessel outperformed fistulas for dialysis access in women, meeting the primary endpoint.
Results presented October 22, 2026, at ASN Kidney Week showed faster usable access and less catheter dependence.
Safety was comparable to fistulas, with fewer dialysis access infections observed among vessel recipients.
Enrollment stopped because the trial met its primary endpoint.
The findings support a planned FDA application this quarter to expand Symvess’ label to include dialysis access.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Humacyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610230800PRIMZONEFULLFEED9851781) on October 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Humacyte's ATEV increases catheter-free days in women in Phase 3 dialysis trial

You may also like

Crypto prices